We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current 50UC market cap is 165.87B. The company's latest EPS is USD 3.8415 and P/E is 27.34.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 24.38B | 26.62B | 37.42B | 44.35B | 45.81B |
| Operating Income | 1.59B | 4.08B | -293M | 3.54B | 7.89B |
| Net Income | 1.34B | 3.2B | 112M | 3.29B | 5.96B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 61.38B | 66.73B | 105.36B | 96.48B | 101.12B |
| Total Liabilities | 46.78B | 51.09B | 66.08B | 59.43B | 61.95B |
| Total Equity | 14.6B | 15.64B | 39.29B | 37.06B | 39.17B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 2.97B | 4.8B | 5.96B | 9.81B | 10.35B |
| Investing | -657M | -285M | -11.06B | -2.96B | -4.06B |
| Financing | -1.77B | -2.2B | 3.65B | -6.82B | -6.57B |
| Market Cap | 165.87B |
| Price to Earnings Ratio | 27.34 |
| Price to Sales Ratio | 3.55 |
| Price to Cash Ratio | 27.88 |
| Price to Book Ratio | 4.16 |
| Dividend Yield | - |
| Shares Outstanding | 1.55B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 4.9 (4.48%) |
| Company Name | Astrazeneca 31 |
| Address |
1 francis crick avenue cambridge CB2 0AA |
| Website | https:// |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
